Our data indicate that HNSCC cells are highly sensitive to hDT806, while these cells have differential sensitivity to the anti-EGFR antibody cetuximab or the EGFR-specific tyrosine kinase inhibitor erlotinib. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.